Thursday 16 October, 2025
Objectives: Meropenem is a beta-lactam antibiotic that is frequently used to treat serious infections in critically ill patients. Previous population…
Read morePoster: Drug/Disease Modelling - Infection
Oral versus intravenous amoxicillin in neonates: a population pharmacokinetic study
Thursday 16 October, 2025
Introduction/Objectives: In neonates, use of oral antibiotics is limited due to lacking evidence on pharmacokinetics (PK) and adequate exposure after…
Read moreCorrelation between trough concentrations and AUC of linezolid for sampling optimization in critically ill patients
Thursday 16 October, 2025
Introduction: Linezolid is an oxazolidinone antibiotic used to treat serious infections caused by drug-resistant gram-positive bacteria. Different pharmacokinetic/pharmacodynamic (PK/PD) targets have…
Read moreProbability of target attainment and dose optimisation of ceftriaxone in children and neonates
Thursday 16 October, 2025
Objectives: Ceftriaxone is a third-generation cephalosporin exhibiting antimicrobial properties for a broad spectrum of bacteria. In both paediatric and adult…
Read moreModeling spatial pharmacokinetics of drugs in mucus in patients with cystic fibrosis
Thursday 16 October, 2025
Introduction: Cystic fibrosis (CF) is a genetic disease causing extensive mucus formation in lung[1], and which is associated with chronic…
Read moreA pharmacometric evaluation of atypical plasma protein binding and probability of target attainment of tigecycline in obese and nonobese patients
Thursday 16 October, 2025
Objectives: Tigecycline is a broad-spectrum antibiotic [1] used to treat complicated intraabdominal infections (cIAI), community acquired pneumonia (CAP) and complicated…
Read moreEvaluating ceftazidime-avibactam exposure in patients undergoing automated peritoneal dialysis using population pharmacokinetic modelling
Thursday 16 October, 2025
Introduction: Ceftazidime/Avibactam (CAZ/AVI) is a recently marketed beta-lactam/beta-lactamase inhibitor antimicrobial combination treatment indicated for use in complicated intra-abdominal infections, complicated…
Read moreSemi-mechanistic model-based analysis of plasma and target-site cefazolin pharmacokinetics and protein binding in obese and nonobese patients
Thursday 16 October, 2025
Objectives: Cefazolin (CEZ) is frequently used for the treatment of skin and soft tissue infections (SSTI), e.g. after surgery. Obesity…
Read morePopulation pharmacokinetics of dolutegravir co-administered with rifampicin in Thai people living with HIV and TB
Thursday 16 October, 2025
Introduction/Objectives Dolutegravir (DTG), a second-generation integrase strand transfer inhibitor (INSTI), is recommended as the first-line treatment for people living with…
Read moreDose Reduction and Population Pharmacokinetics of Lopinavir/ritonavir with and without Rifampin in Thai HIV-infected patients
Thursday 16 October, 2025
Introduction/Objectives: Lopinavir/Ritonavir (LPV/r) is an alternative drug in HIV-1 treatment when the first-line drugs cannot be used [1]. Currently, the…
Read more